IL2 and neoplasm: Neither gender, time from primary tumour to occurrence of metastases (<12 months vs ⩾12 months), type of first-line immunotherapy (IL-2-based treatment vs IFNα alone), number of sites before second-line treatment (1 vs >1) nor general status (Karnofsky ⩾90 vs <90%) reached statistical significance.